» Articles » PMID: 33496855

Lack of Awareness of Liver Organ Damage in Patients with Type 2 Diabetes

Overview
Journal Acta Diabetol
Specialty Endocrinology
Date 2021 Jan 26
PMID 33496855
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Aims: Liver steatosis, a typical finding in patients with type 2 diabetes (T2D), can lead to cirrhosis and hepatocellular carcinoma. The aim of the present study is to estimate the awareness of liver disease among patients with T2D and whether it differs according to the degree of liver fibrosis estimated by transient elastography (TE).

Methods: This is a population-based cross-sectional study. We included all patients with T2D that participated in the 2017-2018 cycle of the National Health and Nutrition Examination Survey and underwent a TE examination. Presence of liver steatosis and fibrosis was assessed by the median values of controlled attenuation parameter and liver stiffness measurement, respectively.

Results: Among the 825 patients included in the analysis, 8.1% (95% CI 5.1%-12.7%) of patients with steatosis were aware of having a liver condition. Even if awareness increased proportionally with increasing severity of organ damage, it remained limited even among patients with advanced fibrosis (17.9%, 95% CI 8.8%-33.3%).

Conclusions: Despite increasing evidence of a frequent hepatic involvement associated with poor prognosis, awareness of suffering of advanced liver disease in patients with T2D is remarkably low, likely reflecting little recognition also among the team of health care professionals.

Citing Articles

The Impact of Silent Liver Disease on Hospital Length of Stay Following Isolated Coronary Artery Bypass Grafting Surgery.

Suffredini G, Le L, Lee S, Gao W, Robich M, Aziz H J Clin Med. 2024; 13(12).

PMID: 38929926 PMC: 11204604. DOI: 10.3390/jcm13123397.


Diagnosis of hepatic steatosis and steatohepatitis in people with new-onset type 2 diabetes: a multidisciplinary approach.

Barana L, Nelva A, Scivetti P, Costanzo M, Fanelli C Endocrine. 2024; 84(2):412-419.

PMID: 38347338 DOI: 10.1007/s12020-024-03715-5.


Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes: Screening, Diagnosis, and Treatment.

Ciardullo S, Vergani M, Perseghin G J Clin Med. 2023; 12(17).

PMID: 37685664 PMC: 10488336. DOI: 10.3390/jcm12175597.


Prevalence of Fatty Liver Disease is Driven by Prediabetes and Diabetes: US NHANES 2017-2018.

Claypool K, Patel C Clin Gastroenterol Hepatol. 2021; 20(3):712-713.

PMID: 33965575 PMC: 10291529. DOI: 10.1016/j.cgh.2021.05.003.

References
1.
Ciardullo S, Sala I, Perseghin G . Screening strategies for nonalcoholic fatty liver disease in type 2 diabetes: Insights from NHANES 2005-2016. Diabetes Res Clin Pract. 2020; 167:108358. DOI: 10.1016/j.diabres.2020.108358. View

2.
Bergqvist C, Skoien R, Horsfall L, Clouston A, Jonsson J, Powell E . Awareness and opinions of non-alcoholic fatty liver disease by hospital specialists. Intern Med J. 2012; 43(3):247-53. DOI: 10.1111/j.1445-5994.2012.02848.x. View

3.
Bjorkstrom K, Franzen S, Eliasson B, Miftaraj M, Gudbjornsdottir S, Trolle-Lagerros Y . Risk Factors for Severe Liver Disease in Patients With Type 2 Diabetes. Clin Gastroenterol Hepatol. 2019; 17(13):2769-2775.e4. DOI: 10.1016/j.cgh.2019.04.038. View

4.
Patel P, Banh X, Horsfall L, Hayward K, Hossain F, Johnson T . Underappreciation of non-alcoholic fatty liver disease by primary care clinicians: limited awareness of surrogate markers of fibrosis. Intern Med J. 2017; 48(2):144-151. DOI: 10.1111/imj.13667. View

5.
Zoppini G, Fedeli U, Gennaro N, Saugo M, Targher G, Bonora E . Mortality from chronic liver diseases in diabetes. Am J Gastroenterol. 2014; 109(7):1020-5. DOI: 10.1038/ajg.2014.132. View